Mycobacterium abscessus (Mab) is a rapidly-growing nontuberculous mycobacterium that 19 is a growing health concern among both immunocompetent and immunocompromised patient 20 populations. It most commonly causes skin and soft tissue or pulmonary infection. As an emerging 21 health issue there is much that still needs to be understood about the infection and its progression 22 to disease. In the context of pulmonary infection, an in vivo system of Mab infection that permits 23 investigation of host-microbe interactions that result in Mab infection and the transition to 24 pathogenesis, and also the evaluation of treatments, is an essential tool that is currently lacking. 25
INTRODUCTION 29
Mycobacterium abscessus (Mab) is a rapidly-growing nontuberculous mycobacterium. 30
This environmental mycobacterium, while often an innocuous colonizer, can cause pathology in 31 the lungs, skin, and other soft tissues. In patients with underlying immunodeficiency and/or lung 32 conditions such as cystic fibrosis or bronchiectasis, Mab can cause a chronic lung infection 1, 2 . 33
Despite the emerging significance of Mab pulmonary infections, a mammalian model that 34 recapitulates the process of aerosol infection and subsequent development of pathology in human 35 disease [3] [4] [5] has not yet been developed. Such a model would be an essential tool to study 36 pathogenesis of Mab disease and to assess efficacy of treatment regimens. 37
In recent years, several attempts have been made to develop models of Mab infection. Models 38 using hosts such as Drosophila 6,7 , zebrafish [8] [9] [10] [11] [12] [13] , and Galleria mellonella larvae 14 have been 39
described, but these models do not capture key aspects of pulmonary infection. As mouse models 40 have been used extensively for the study of pulmonary M. tuberculosis infection and disease 18 , it is relevant to assess if the mouse can serve as a host to develop a model of pulmonary Mab 42 disease that is representative of aspects of human infection and pathology. We therefore turned 43 to the mouse to develop a system of pulmonary Mab infection that utilizes the aerosol route for 44 infection, and leads to an increase in lung bacterial burden after implantation resulting in the 45 formation of gross lung lesions. Several studies have generated significant insights into infection 46 dynamics of Mab in various genetic backgrounds of mice and demonstrated that 47 immunocompetent mice gradually clear the infection, while certain immunodeficient mice can 48 sustain chronic infection. The intravenous route of infection used in four of these studies 19 burden in C57BL/6 mice using a modified fibrin plug model of intratracheal infection, but clearance 57 of the infection did occur in "cystic fibrosis" S489X Cftr mutation mice 25 . 58
Several papers have attempted to bypass these more invasive modes of infection in favor 59 of the aerosolization method, with varying degrees of success. Ordway et Tables 1 and 2 , respectively. Cortisone (Sigma-Aldrich C2755) 115 and dexamethasone (Sigma-Aldrich D1756) were dissolved in sterile 1x phosphate buffered 116 saline, pH 7.4 (Quality Biological, 114-058-101) and administered by sub-cutaneous injection, 117 200 µL bolus using 26 gauge syringe, as described previously 34, 36, 38, 39 . 118 119 Study 1: We used Nude and C3HeB/FeJ mice. C3HeB/FeJ mice were divided into two groups. 120
The first group did not receive any corticosteroid. The second group received cortisone daily (7 121 days/week, 40 mg/kg) beginning two days prior to infection. A cortisone dose of 40 mg/kg and 122 daily dosing frequency were selected based on published usage in Mtb infection models 36, 38 . The 123 athymic Nude mouse group acted as a comparison to observations reported in the literature 19, 20 . 124
All mice were infected simultaneously by aerosolizing 10 mL of Mab suspension, A 600nm = 1.0. 125
Lungs were dissected at twenty-four hours post-infection to enumerate the CFU implanted during 126 infection and then at two, four and six weeks post-infection to determine dynamics of infection. A 127 schematic of this study is outlined in 
RESULTS

146
Study 1: The burden of Mab in the lungs of mice are shown in Figure 1A . On the day after 147 infection, similar Mab CFU counts were found in the lungs of the three groups of mice: Nude, 148 untreated C3HeB/FeJ and C3HeB/FeJ treated with cortisone for two days. In the lungs of 149 untreated C3HeB/FeJ mice, Mab burden declined gradually initially (mean CFU of 3.4 log 10 to 2.8 150 log 10 from day zero to week two) and then more rapidly after two weeks (mean CFU of 2.8 log 10 151 to 0.3 log 10 from week two to week four). Similarly, Mab burden also declined in the lungs of Nude 152 mice, but at a more gradual rate. The mean CFU from day zero was 3.6 log 10 , while at week two 153 it was within one standard deviation at 3.5 log 10 , but then declined to 2.7 log 10 at week four and 154 1.1 log 10 at week six. In C3HeB/FeJ mice receiving cortisone, the lung burden was relatively stable 155 for the first two weeks (mean CFU of 3.6 log 10 at day zero and 3.9 log 10 at two weeks), followed 156 by a rapid increase thereafter to 4.8 log 10 at week four and 6.6 log 10 at week six. At week six one 157 mouse that received cortisone developed a pulmonary lesion (Figure 1B) . 158 159 Study 2: We initiated a new study with the aim to reproduce and verify Mab proliferation and 160 lesion formation observed in the lungs of C3HeB/FeJ mice in Study 1. Compared to Study 1, we 161 administered immunosuppressive treatment for a longer period prior to infection with the intention 162 to decrease the variability in CFU burden observed at two weeks, which was thought to be due to 163 incomplete immunosuppression at infection and in the weeks following. 164
Mab burden in the lungs are shown in Figure 2 . These infections resulted in an initial 165 pulmonary implantation of 3.9±0.11 log 10 and 4.4±0.10 log 10 CFU for low and high Mab doses, 166
respectively, averaged across all groups. Two weeks after infection, we observed a rapid increase 167 
A B
1 cm in bacterial burden in the lungs of mice treated with cortisone or dexamethasone. For cortisone 168 regimen mice with low dose and high dose infection, this meant an increase to 6.8 log 10 and 6.7 169 log 10 mean CFU, and for dexamethasone regimen mice with low dose and high dose infection an 170 increase to 8.7 log 10 and 7.9 log 10 CFU. In the untreated mice at this same timepoint we observed 171 a decrease to a mean CFU of 2.8 log 10 in the low dose infection and 4.1 log 10 in the high dose 172 infection. We also observed bacterial dissemination to the liver and spleen in some of the mice 173 (Tables 3, 4 , and Supplement Table 1) . 174
Shortly after discontinuing treatment, three mice infected with a high dose of Mab and 175 treated with cortisone died. Similarly, in groups infected with high and low doses of Mab and 176 treated with dexamethasone, three and nine mice died, respectively. There were no deaths in 177 mice infected with low dose Mab and treated with cortisone. 178
At the week four time point, we observed a decrease in the average Mab burden in the 179 lungs of mice in all groups. In untreated mice, lung bacterial burden decreased further to a mean 180 CFU of 1.6 log 10 CFU for low dose infection and to a mean CFU of 2.0 log 10 for high dose infection 181 over this two week period. For cortisone regimen mice with low dose and high dose infection 182 mean CFU decreased to 3.3 log 10 and 4.4 log 10 , and for dexamethasone regimen mice with low 183 dose and high dose infection they decreased to 6.8 log 10 and 6.6 log 10 mean CFU. The bacterial 184 burden in the liver and spleen, however, continued to increase or remained stable from week two 185 (Tables 3 & 4) . 186
Of note there was an increase in the variability of the lung bacterial burden at this timepoint 187 compared to earlier timepoints, specifically in the dexamethasone regimen groups with both low 188 and high infection doses. Data detailing the weights of all mice in this experiment along with their 189 respective bacterial burdens at the sampled sites (Supplement Table 1 
DISCUSSION 213
Our aim was to develop a system of pulmonary Mab infection in mice that utilizes the 214 aerosol route of infection, leads to an increase in lung bacterial burden after implantation, and 215 develops pulmonary lesions due to infection. The studies of Mab infection that have been 216 performed in mice thus far have unfortunately failed to achieve these goals in an 217 immunocompetent mouse strain. The study presented here describes a sustained Mab pulmonary 218 infection via aerosolization in an immunocompetent mouse strain with corticosteroid-induced 219 immune suppression. 220
Our first study affirmed that cortisone treatment in mice allows for a gradual increase in 221 bacterial burden ( Figure 1A) . However, there was large variability in the bacterial burden at two 222 weeks post-infection and a more uniformly higher bacterial burden was not observed until the 223 week four timepoint. The variability in bacterial burden suggested that a longer duration of 224 corticosteroid treatment prior to infection may be beneficial in increasing the initial bacterial 225 burden in the lungs. Alternatively, this variability may also be explained by the mouse strain itself. 226 C3HeB/FeJ mice are known to have variable infection outcomes when infected with M. 227 tuberculosis 16, 17 . To test this first hypothesis, we extended the corticosteroid regimen prior to 228 infection in our second study. Here we observed the CFU in the lungs of mice treated with either 229 cortisone or dexamethasone rapidly increased by the week two timepoint and did demonstrate 230 decreased variability at this timepoint. We also observed dissemination to the liver and spleen in 231 corticosteroid regimen mice, which did not occur to the same extent in untreated mice. As noted 232 previously, several of the corticosteroid regimen mice subsequently died following cessation of 233 steroids. However, these mice subjectively appeared to be sicker, of lower body weight, and 234 seemed likely to die from the infection even prior to stopping treatment suggesting that the level 235 of immune suppression was perhaps too high, especially in the dexamethasone-treated group. 236 
